Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System
ConclusionOver one third of patients with stable ASCVD may qualify for low-dose rivaroxaban within the VA. Additional studies are needed to understand eligibility in other populations and a formal cost-effectiveness analysis is warranted.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Endocrinology | Heart | Hypertension | Students | Study | Universities & Medical Training